The current situation regarding ACE-031 1mg's presence in Europe is complex . Despite initial approvals have been granted in certain nations , widespread availability remains restricted . In particular , individual usage is currently based on individual administrative procedures and therapeutic structures . Therefore , complete assessment of its re